Molecular Targeting Technologies, Inc. develops targeted radiopharmaceuticals and molecular-imaging technologies for cancer and other diseases, alongside research reagents such as CellVue® and NeuroVue® fluorescent dyes. Based in West Chester, Pennsylvania, the company’s work spans clinical-stage platforms including EBTATE® and EvaThera, as well as custom affinity absorbents and laboratory products. Its leadership brings extensive experience in radiopharmaceutical development, nuclear medicine, fluorescent chemistry, and biopharmaceutical regulation.
Molecular Targeting Technologies, IncPrivately held and clinical-stage, Molecular Targeting Technologies, Inc. is known for advancing radiopharmaceutical research aimed at rare cancers. Its EvaThera platform, licensed worldwide from the National Institutes of Health, supports targeted diagnosis and treatment for patients whose tumors express specific molecular markers.WEST CHESTER, PA
SOFIE BiosciencesSOFIE Biosciences develops and manufactures radiopharmaceuticals for molecular imaging and theranostic applications. Founded in 2006, the company combines a radiopharmacy production and distribution network with contract manufacturing and the development of FAPI diagnostic compounds. Its radiopharmacy sites produce and deliver imaging agents across the United States, while its contract manufacturing work supports research, clinical trials, and commercial supply.COLONIE, NY
Akrotome ImagingIncorporated in Delaware in late 2008, Cleveland-based Akrotome Imaging develops fluorescent molecular probes that help surgeons see cancer and its margins during resection. Its patented FIRE platform uses quenched probes that activate when they encounter tumor-associated enzymes, with the flexibility to be applied in the operating room and used alongside a near-infrared imaging system. The company’s current team has been in place since 2012 and is translating the technology toward breast and non-melanoma skin cancer applications.CLEVELAND, OH
Modulation TherapeuticsFounded in 2011 as a Moffitt Cancer Research Center spinoff, Modulation Therapeutics is a Morgantown clinical-stage biotechnology company developing therapies for aggressive solid-tumor cancers and liver disease. Its research team combines targeted alpha radiotherapy with peptide and small-molecule drug development, including a therapy for metastatic melanoma that has received FDA Orphan Drug and Fast Track designations. The privately held company moved its primary operations to West Virginia in 2016 and works with West Virginia University researchers to advance its pipeline toward clinical use.MORGANTOWN, WV